Rhenman & Partners Asset Management’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.8M Sell
90,000
-206,000
-70% -$19.7M 0.96% 44
2025
Q4
$28.4M Buy
296,000
+91,000
+44% +$8.84M 2.66% 4
2025
Q3
$19.5M Buy
205,000
+25,500
+14% +$2.34M 2.16% 13
2025
Q2
$15.6M Sell
179,500
-75,500
-30% -$6.4M 1.98% 18
2025
Q1
$22.9M Sell
255,000
-14,500
-5% -$1.3M 2.63% 11
2024
Q4
$21.5M Sell
269,500
-98,500
-27% -$8.53M 2.21% 14
2024
Q3
$33.1M Buy
368,000
+160,000
+77% +$13.5M 2.69% 8
2024
Q2
$16.4M Sell
208,000
-117,000
-36% -$9.59M 1.57% 22
2024
Q1
$28.3M Sell
325,000
-266,000
-45% -$22.7M 2.68% 12
2023
Q4
$48.7M Buy
591,000
+216,000
+58% +$16.5M 4.86% 1
2023
Q3
$29.4M Buy
375,000
+83,000
+28% +$6.95M 3.17% 6
2023
Q2
$25.7M Buy
292,000
+57,000
+24% +$4.91M 2.71% 8
2023
Q1
$18.6M Sell
235,000
-115,000
-33% -$9.37M 2.04% 20
2022
Q4
$27.2M Buy
350,000
+110,000
+46% +$8.92M 2.84% 3
2022
Q3
$21M Buy
240,000
+90,000
+60% +$8.09M 2.2% 16
2022
Q2
$13.5M Sell
150,000
-10,000
-6% -$1.01M 1.53% 25
2022
Q1
$17.8M Sell
160,000
-136,000
-46% -$14.4M 1.75% 20
2021
Q4
$30.9M Buy
296,000
+23,000
+8% +$2.66M 2.06% 14
2021
Q3
$34.2M Hold
273,000
2.4% 10
2021
Q2
$33.9M Sell
273,000
-62,000
-19% -$7.78M 2.3% 8
2021
Q1
$39.6M Buy
335,000
+15,000
+5% +$1.76M 2.76% 6
2020
Q4
$37.5M Buy
320,000
+99,220
+45% +$10.9M 3.06% 4
2020
Q3
$22.9M Buy
220,780
+90,000
+69% +$9.04M 2.04% 17
2020
Q2
$12M Hold
130,780
1.3% 33
2020
Q1
$11.8M Buy
130,780
+5,750
+5% +$612K 1.65% 23
2019
Q4
$14.2M Sell
125,030
-60,188
-32% -$6.6M 1.55% 26
2019
Q3
$20.1M Buy
185,218
+22,335
+14% +$2.33M 2.52% 9
2019
Q2
$15.9M Sell
162,883
-5,959
-4% -$544K 1.75% 22
2019
Q1
$15.4M Sell
168,842
-131,561
-44% -$11.8M 1.8% 21
2018
Q4
$27.3M Buy
300,403
+50,529
+20% +$4.72M 3.12% 3
2018
Q3
$24.6M Sell
249,874
-30,000
-11% -$2.77M 2.46% 8
2018
Q2
$24M Buy
279,874
+68,591
+32% +$5.73M 2.45% 8
2018
Q1
$16.9M Buy
211,283
+47,058
+29% +$3.88M 2.09% 17
2017
Q4
$13.3M Sell
164,225
-49,890
-23% -$4M 1.79% 21
2017
Q3
$16.7M Buy
214,115
+23,000
+12% +$1.91M 2.13% 13
2017
Q2
$17M Buy
191,115
+10,000
+6% +$843K 2.44% 9
2017
Q1
$14.6M Sell
181,115
-34,125
-16% -$2.67M 2.31% 8
2016
Q4
$15.3M Buy
+215,240
New +$16.9M 2.94% 5
2016
Q3
Sell
-127,000
Closed -$11M 114
2016
Q2
$11M Sell
127,000
-10,000
-7% -$809K 1.96% 15
2016
Q1
$10.3M Sell
137,000
-112,000
-45% -$8.44M 2.04% 12
2015
Q4
$19.2M Sell
249,000
-16,000
-6% -$1.2M 2.9% 3
2015
Q3
$17.7M Buy
265,000
+110,200
+71% +$8.12M 2.83% 3
2015
Q2
$11.5M Buy
154,800
+85,800
+124% +$6.56M 1.38% 21
2015
Q1
$5.38M Buy
69,000
+34,000
+97% +$2.58M 0.91% 41
2014
Q4
$2.53M Sell
35,000
-98,800
-74% -$6.86M 0.73% 58
2014
Q3
$6.87M Buy
+133,800
New +$8.51M 2.01% 9
2014
Q2
Sell
-39,429
Closed -$2.43M 103
2014
Q1
$2.43M Sell
39,429
-35,571
-47% -$2.07M 0.73% 50
2013
Q4
$4.3M Buy
+75,000
New +$4.25M 1.68% 19

Other funds holding MDT

Rhenman & Partners Asset Management's MDT Position: Q1 2026 in Review

Rhenman & Partners Asset Management reduced its Medtronic (MDT) stake by 70% in Q1 2026, selling an estimated $19.7M and leaving 90,000 shares worth $7.8M. The position accounts for 0.96% of the portfolio, ranked #44.

Rhenman & Partners Asset Management first reported a position in MDT in Q4 2013 and has held it in 48 quarters since. The position peaked at $48.7M in Q4 2023. 2,231 funds tracked by Wall St. Rank hold MDT as of Q1 2026.

  • Rhenman & Partners Asset Management held 90,000 shares of Medtronic worth $7.8M as of Q1 2026.
  • Rhenman & Partners Asset Management sold 206,000 Medtronic shares in Q1 2026, an estimated $19.7M.
  • Medtronic made up 0.96% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #44 holding.
  • Rhenman & Partners Asset Management first reported a position in Medtronic in Q4 2013 and has held it in 48 quarters since.
  • Rhenman & Partners Asset Management's Medtronic position peaked at $48.7M in Q4 2023.
  • 2,231 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.